Marco Cerrano

35PUBLICATIONS
151CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|May 21, 2026
T-cell acute lymphoblastic leukemia in adults: current treatment approaches and future perspectives.

|Dec 05, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Sep 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Fabio Guolo, Luana Fianchi, Maria Paola Martelli

|Aug 11, 2025
Real World Incidence and Etiology of Infectious Complications in Adults With Ph-Negative Acute Lymphoblastic Leukemia Treated With the Pediatric-Inspired GIMEMA LAL1913 Program. A Campus All Study.

Patrizia Zappasodi, Ludovica Calabretta, Virginia Valeria Ferretti

|Aug 08, 2025
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.

Alessandra Iurlo, Massimo Breccia, Fabio Stagno

|Mar 06, 2025
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Giovanni Marconi, Alfonso Piciocchi, Ernesta Audisio

Pageof 6

Frequent Collaborators

7 joint publications

Fabio Guolo

4 joint publications

Paola Minetto

4 joint publications

Livio Pagano

4 joint publications

Adriano Venditti